List of Excipients in Branded Drug DICLOFENAC SODIUM GEL

« Back to Dashboard

Generic Drugs Containing DICLOFENAC SODIUM GEL

Company	Ingredient	NDC	Excipient
Direct_Rx	diclofenac sodium gel	72189-379	BENZYL ALCOHOL
Direct_Rx	diclofenac sodium gel	72189-379	HYALURONATE SODIUM
Direct_Rx	diclofenac sodium gel	72189-379	PEG-6 METHYL ETHER
Direct_Rx	diclofenac sodium gel	72189-379	WATER
Direct_Rx	diclofenac sodium gel	72189-473	BENZYL ALCOHOL
Direct_Rx	diclofenac sodium gel	72189-473	HYALURONATE SODIUM

What are the Most Frequently-Used Excipients in DICLOFENAC SODIUM GEL?

# Of NDCs	Excipient
1	AMMONIA
2	BENZYL ALCOHOL
2	CARBOMER HOMOPOLYMER TYPE C
2	COCO-CAPRYLATE/CAPRATE
2	HYALURONATE SODIUM
2	ISOPROPYL ALCOHOL

Diclofenac Sodium Gel Excipient Strategy and Commercial Opportunities

Last updated: October 7, 2026

Diclofenac sodium gel is a mature topical NSAID platform with broad generic availability, established consumer demand, and multiple opportunities for differentiation. The strongest commercial strategies are not based on the active ingredient alone. They depend on skin delivery, sensory profile, transfer resistance, packaging, tolerability, regulatory pathway, and protection of formulation know-how.

For the U.S. market, Voltaren Arthritis Pain Gel contains diclofenac sodium 1% and is marketed over the counter for temporary relief of arthritis pain in certain joints. Prescription diclofenac sodium topical gel 1% products also remain commercially relevant. The formulation platform uses a hydroalcoholic, carbomer-based gel with penetration-supporting excipients and neutralization of the polymer to produce the final rheology profile.[1,2]

What excipients are used in diclofenac sodium gel?

The established 1% diclofenac sodium gel platform uses excipients that perform separate functions: polymeric thickening, solvent control, skin penetration, emollience, surfactant activity, pH adjustment, and preservation.

Representative Voltaren gel excipient system

Excipient or component	Primary function in the gel	Commercial relevance
Carbomer	Gelling and viscosity control	Controls spreadability, residence time, and dose uniformity
Propylene glycol	Cosolvent and humectant	Supports diclofenac solubilization and skin hydration
Isopropyl alcohol	Volatile solvent and sensory modifier	Promotes rapid drying and cooling sensation
Mineral oil	Emollient and skin-conditioning agent	Reduces harshness from alcohol and supports feel
Polyoxyl 20 cetostearyl ether	Surfactant and solubilizer	Supports dispersion and physical stability
Cocoyl caprylocaprate	Emollient and penetration-supporting vehicle	Improves glide and skin feel
Diethylamine	Neutralizing agent and salt-forming component	Adjusts carbomer gel structure and supports diclofenac solubility
Purified water	Continuous phase	Provides the aqueous vehicle

The commercial formulation should not be treated as a simple mixture of diclofenac sodium and carbomer. The excipient ratios determine whether the product has acceptable viscosity, drying time, drug release, skin permeation, packaging compatibility, and user acceptance.[1]

Which excipients create the main technical risks?

The principal risks are precipitation, viscosity drift, drug crystallization, phase separation, microbial contamination, and excessive skin irritation.

Carbomer concentration and neutralization must be optimized together. Excessive polymer or neutralizer can produce a stiff gel with poor spreadability. Insufficient polymer can create runny application behavior, poor dose retention, and inconsistent delivery.

Alcohol and propylene glycol can improve drug release and skin penetration, but higher levels may increase burning, dryness, or irritation. Emollients can reduce irritation, although excessive oil loading can slow drying and create a greasy residue.

Surfactants may improve solubilization but can increase irritation risk and complicate preservative performance. The final system requires compatibility testing across pH, temperature, freeze-thaw cycles, and long-term storage.

How should a diclofenac sodium gel excipient strategy be designed?

A successful development program should begin with a target product profile rather than a direct copy of the reference product.

Target product profile

Attribute	Commercial target
Diclofenac strength	Usually 1% for arthritis-pain products
Dosage form	Topical gel with uniform dose delivery
Appearance	Clear to translucent, homogeneous gel
Skin feel	Fast-spreading, low residue, low tack
Drying time	Short enough for routine daytime use
Irritation	Low stinging and low dryness
Drug release	Consistent release across shelf life
Packaging	Tube, pump, or metered-dose container
Stability	Adequate chemical, physical, and microbiological stability
Regulatory route	ANDA, OTC monograph-related pathway, or full NDA depending on product and market

The formulation should be optimized using design-of-experiments methods covering polymer grade, polymer concentration, neutralizer level, solvent ratio, surfactant concentration, oil phase, and pH. Critical quality attributes should include viscosity, yield stress, spread diameter, drying time, diclofenac assay, degradation products, in-vitro release, skin permeation, microbial limits, and package extractables.

Which formulation approaches can differentiate a generic gel?

The most commercially credible approaches are:

1. Lower-residue hydroalcoholic gel.
   This approach reduces tack and greasy feel while preserving drug release.

2. Reduced-irritation system.
   Lower alcohol, lower surfactant burden, or replacement of selected solvents can improve tolerability for frequent users.

3. Enhanced skin-delivery formulation.
   Solvent and emollient combinations can improve local delivery without increasing systemic exposure. Any enhancement claim requires controlled comparative testing.

4. Preservative-reduced or preservative-free packaging.
   Airless pumps and unit-dose systems can reduce contamination risk, but they raise device cost and require container-closure validation.

5. Metered-dose delivery.
   A pump can improve dose consistency and reduce uncertainty associated with squeezing a tube.

6. Sensitive-skin variant.
   Products with reduced fragrance, lower alcohol, and less aggressive surfactant systems could target consumers who discontinue topical NSAIDs because of irritation.

7. Non-staining or low-transfer formulation.
   A rapid-drying system may be valuable for daytime use and for users who wear clothing over the application site.

What regulatory pathways apply to diclofenac sodium gel?

In the United States, the regulatory pathway depends on the intended product and labeling.

Prescription diclofenac sodium gel

Prescription diclofenac sodium topical gel 1% products generally use an abbreviated new drug application when the applicant can demonstrate pharmaceutical equivalence and bioequivalence to the reference listed drug. The applicant must address active ingredient strength, dosage form, route, inactive ingredients, performance, and product quality.

Topical products may require comparative in-vitro release testing, pharmacokinetic studies, or other evidence depending on FDA requirements and the reference product. A formulation with materially different excipients or a novel delivery system may increase development complexity.

OTC Voltaren Arthritis Pain Gel

Voltaren Arthritis Pain Gel is an OTC product for temporary relief of arthritis pain in specific joints. FDA approved the switch of diclofenac sodium topical gel 1% from prescription to nonprescription status in 2020.[3] The OTC product carries consumer-directed labeling, including use limitations, dosing instructions, warnings, and restrictions associated with NSAID products.

A company developing an OTC competitor must consider both the drug facts labeling and the consumer-use environment. Sensory characteristics, package usability, dosing instructions, and claim language have direct commercial importance.

What FDA quality issues are most important?

FDA review is likely to focus on:

• Uniformity of diclofenac content and dose delivery
• Drug release and permeation performance
• Physical and chemical stability
• Degradation products
• Microbial quality
• Container-closure compatibility
• Leachables and extractables
• Irritation and sensitization risk
• Manufacturing controls for carbomer hydration and neutralization
• Control of alcohol loss during filling and storage

Changes to excipient identity or level can alter drug release and may require additional comparative studies. A formulation that is chemically equivalent but materially different in rheology may not provide a low-risk regulatory bridge.

What patents protect diclofenac sodium gel products?

Diclofenac sodium gel patent protection is generally more fragmented than protection for a new chemical entity. Key categories include:

Patent category	Typical protected subject matter	Commercial importance
Composition patents	Diclofenac with defined solvent, polymer, surfactant, or emollient combinations	Can create formulation-specific barriers
Method-of-use patents	Treatment of arthritis pain, osteoarthritis, or specific joints	May affect label design and induced-infringement risk
Manufacturing patents	Mixing sequence, neutralization, homogenization, filling, or stability control	Can protect process know-how
Device patents	Pumps, applicators, metered-dose systems, or dispensing mechanisms	Relevant to differentiated packaging
Trade secrets	Exact ratios, processing conditions, and scale-up parameters	Often important after composition patents expire

The original product and subsequent formulations have been the subject of historical patent filings, but patent relevance depends on jurisdiction, claim scope, terminal disclaimers, prosecution history, maintenance, and litigation outcomes. FDA Orange Book listings are most directly relevant to approved prescription products, while an OTC product may not provide the same Orange Book visibility as a prescription NDA.[4]

When does diclofenac sodium gel lose exclusivity?

The active ingredient is long established, and basic composition protection for conventional diclofenac sodium gel is generally no longer the main market barrier. Commercial exclusivity is more likely to arise from:

• Remaining formulation claims
• Method-of-use claims
• Pediatric or other regulatory exclusivity, where applicable
• Device or packaging patents
• Brand recognition and OTC shelf position
• Manufacturing know-how
• Retail distribution and advertising scale

A current freedom-to-operate review should evaluate issued and pending claims in the United States, European Union, Canada, Japan, China, Australia, and other target markets. Patent expiration cannot be inferred from the existence of a historical patent filing because patent term adjustments, continuations, divisionals, national-phase rights, and claim amendments may change the relevant analysis.[4,5]

What generic entry risks exist for diclofenac sodium gel?

Generic entry risk is high for conventional 1% diclofenac sodium gel because the active ingredient is established, manufacturing is technically accessible, and multiple suppliers can produce carbomer-based topical gels.

The highest risk applies to a product that:

• Uses standard excipients
• Has no meaningful sensory advantage
• Relies on tube packaging
• Makes the same claims as existing products
• Competes mainly on price
• Has no differentiated distribution strategy

The risk is lower for a product with a defensible combination of formulation, device, and brand attributes. A new product can still face rapid substitution if its differentiation is not visible to pharmacists, retailers, physicians, or consumers.

How do Paragraph IV challenges affect diclofenac gel?

A Paragraph IV certification can challenge an Orange Book-listed patent associated with a prescription reference product. The generic applicant may argue that the listed patent is invalid, unenforceable, or not infringed. The patent holder can bring litigation, potentially triggering a 30-month stay under the Hatch-Waxman framework, subject to statutory conditions and court developments.[6]

For diclofenac sodium gel, the commercial impact of a Paragraph IV filing depends on whether the challenged patent covers the active formulation, a method of use, or a narrower product attribute. A generic applicant may design around a formulation claim while retaining the same strength and dosage form.

Which companies compete in diclofenac sodium gel?

The competitive field includes Haleon, through Voltaren Arthritis Pain Gel in the United States, and multiple generic manufacturers marketing prescription or OTC diclofenac topical products in different jurisdictions. Manufacturers and marketers vary by country, and ownership can change through licensing, acquisition, contract manufacturing, or local commercialization agreements.

Competition generally falls into four groups:

1. Branded OTC products, which compete through consumer awareness, pharmacy placement, and advertising.
2. Prescription generics, which compete through formulary access, wholesaler relationships, and price.
3. Private-label products, which compete through retailer distribution and lower marketing expense.
4. Premium delivery systems, which seek higher margins through sensory or device differentiation.

Biosimilar risk is not relevant to diclofenac sodium gel because diclofenac sodium is a chemically synthesized small-molecule drug, not a biologic. The relevant competitive threats are generic substitution, private-label entry, reformulated products, and alternative topical NSAIDs such as diclofenac diethylamine, diclofenac epolamine, ketoprofen, and ibuprofen products.

How does diclofenac sodium gel compare with competing topical NSAIDs?

Product class	Main advantage	Main limitation	Commercial implication
Diclofenac sodium gel	Strong brand history and broad evidence base	Mature category with price pressure	Best opportunity is formulation or channel differentiation
Diclofenac diethylamine gel	Established topical delivery platform in several markets	Different salt and regulatory comparability issues	May offer regional licensing opportunities
Diclofenac epolamine patch or gel	Alternative delivery and convenience	Higher device or manufacturing cost	Supports premium positioning
Ketoprofen topical products	Established anti-inflammatory category	Photosensitivity and regional restrictions can affect use	Regulatory and safety profile must be managed
Ibuprofen gel	Familiar OTC NSAID	May have weaker brand positioning in some markets	Price competition is likely intense

The strongest choice depends on jurisdiction, indication, regulatory status, reimbursement, and the ability to demonstrate a clinically or commercially meaningful advantage.

What licensing and manufacturing opportunities exist?

Diclofenac sodium gel has licensing potential in four areas.

Formulation licensing

A supplier with a lower-irritation, faster-drying, or higher-stability formulation can license the formulation to regional pharmaceutical companies. The agreement may include an upfront fee, development milestones, royalties, minimum purchase commitments, and territory-specific rights.

Private-label manufacturing

Contract manufacturers can supply retailer brands using a common base formulation. The economics depend on batch scale, packaging format, testing requirements, and forecast reliability.

Device partnerships

Metered-dose pumps and airless containers can support co-development deals. Device IP may be more durable commercially than a conventional gel composition, particularly when it improves dosing consistency or reduces contamination.

Regional commercialization

A company with regulatory approval and manufacturing capacity can license rights to distributors in markets where topical NSAIDs are widely used but branded penetration is lower. The European Union, Asia-Pacific, Latin America, and Middle East markets require country-specific analysis of salt form, indication, prescription status, labeling, and patent rights.

Manufacturing barriers are moderate. The process requires controlled polymer dispersion, neutralization, solvent management, deaeration, filling, and package compatibility. The main scale-up risks are air entrapment, viscosity variation, alcohol evaporation, nonuniform drug distribution, and batch-to-batch changes in spreadability.

What is the revenue exposure for a diclofenac sodium gel portfolio?

Revenue exposure is concentrated in retail and pharmacy channels rather than hospital procurement. The product is typically a high-volume, moderate-margin topical medicine. Branded OTC revenue depends on advertising, shelf placement, and repeat use. Generic revenue depends on tender access, pharmacy substitution, wholesaler terms, and manufacturing cost.

A portfolio can improve economics by combining:

• A low-cost generic tube
• A premium pump formulation
• A sensitive-skin variant
• Private-label supply
• Regional licensing
• Contract manufacturing
• Complementary topical pain products

The principal risk is cannibalization. A premium variant may shift existing users from a higher-margin product without expanding total category demand. Portfolio architecture should therefore separate products by consumer need, channel, packaging, and price.

How strong is the patent estate for diclofenac sodium gel?

The patent estate is usually weaker for a basic 1% diclofenac sodium gel than for a novel drug or biologic. The strongest protection is likely to come from narrow formulation claims, device claims, manufacturing claims, and carefully drafted method-of-use claims rather than broad claims covering diclofenac gel generally.

A defensible strategy should combine:

• A composition patent directed to a defined excipient ratio
• A method patent directed to a measurable delivery or tolerability outcome
• A device patent covering metered dispensing
• Trade-secret protection for manufacturing parameters
• Regulatory exclusivity where available
• Brand and channel control

Patent strength should be assessed by claim breadth, written-description support, enablement, prosecution history, prior-art density, and the ease with which a competitor can substitute one excipient without losing the claimed performance.

Key Takeaways

• Diclofenac sodium gel is a mature, genericized topical NSAID platform with high competitive entry risk.
• The core excipient system typically combines carbomer, propylene glycol, alcohol, emollients, surfactants, water, and a neutralizer.
• The most valuable formulation improvements involve irritation, drying time, residue, dose consistency, stability, and packaging.
• OTC and prescription products require different regulatory and patent analyses.
• Paragraph IV risk is relevant where an applicant challenges Orange Book-listed patents for a prescription reference product.
• Biosimilar competition is not relevant because diclofenac sodium is a small-molecule drug.
• The strongest commercial opportunities are premium delivery systems, sensitive-skin formulations, private-label manufacturing, and regional licensing.
• Basic composition patents are unlikely to provide broad exclusionary power; device, process, narrow formulation, and trade-secret protections are more practical.
• Manufacturing is accessible, but scale-up control of carbomer hydration, neutralization, solvent loss, deaeration, and filling is important.
• A differentiated formulation must produce a visible consumer benefit or a measurable regulatory and commercial advantage.

FAQs

Is diclofenac sodium gel water-based or alcohol-based?

It is generally a hydroalcoholic gel containing water and a volatile alcohol, commonly isopropyl alcohol, together with propylene glycol and polymeric thickener.

Can propylene glycol be removed from diclofenac sodium gel?

It can be replaced or reduced, but the change may affect diclofenac solubility, drug release, skin permeation, viscosity, irritation, and stability. Comparative product-performance testing is required.

Is a preservative-free diclofenac gel commercially viable?

It can be viable if the formulation and packaging control microbial risk. Airless pumps, unit-dose systems, and validated container-closure designs can support the proposition, although they generally increase packaging cost.

Does a thicker diclofenac gel deliver more drug?

Not necessarily. Higher viscosity may increase residence time but can reduce spreadability and alter release. Drug delivery depends on the combined effects of polymer concentration, solvent composition, pH, drug solubility, and skin interaction.

Can a company patent a new diclofenac sodium gel formulation?

Yes, if the formulation satisfies patentability requirements and provides adequate technical support. The strongest claims usually identify a specific excipient combination, performance characteristic, delivery system, or manufacturing process rather than diclofenac gel in broad terms.

References

1. DailyMed. (2024). Voltaren Arthritis Pain topical gel: Diclofenac sodium 1% labeling. U.S. National Library of Medicine.
2. U.S. Food and Drug Administration. (2024). Diclofenac sodium topical gel, 1% prescribing information. FDA.
3. U.S. Food and Drug Administration. (2020). FDA approves first over-the-counter topical gel for arthritis pain. FDA.
4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
5. United States Patent and Trademark Office. (2024). Patent term adjustment and patent term information. USPTO.
6. U.S. Food and Drug Administration. (2024). Abbreviated new drug application submissions and patent certifications under the Hatch-Waxman Amendments. FDA.